

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate hazard ratio for progression-free survival in the Phase III MajesTEC-3 study evaluating teclistamab with daratumumab versus investigator's choice of daratumumab/pomalidomide/dexamethasone or daratumumab/bortezomib/dexamethasone for patients with relapsed/refractory (R/R) multiple myeloma (MM)?
 - a. 0.17
 - b. 0.39
 - c. 0.65
 - d. 0.80
2. Which of the following descriptions best represents the study design of the EXCALIBER-RRMM trial?
 - a. A Phase I/II study evaluating iberdomide/cyclophosphamide/dexamethasone for R/R MM
 - b. A Phase I/II study evaluating mezigdomide/daratumumab/bortezomib/dexamethasone for newly diagnosed MM
 - c. A Phase III study evaluating iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
 - d. A Phase III study evaluating mezigdomide/carfilzomib/dexamethasone versus pomalidomide/carfilzomib/dexamethasone for R/R MM
3. Which of the following results was reported from the Phase I/II LINKER-MM1 trial of linvoseltamab for patients with R/R MM?
 - a. Low response rate (<30%) with short duration of response (DoR, median ~9 months)
 - b. Low response rate (<30%) with durable responses (median DoR ~29 months)
 - c. High response rate (>70%) with short DoR (median ~9 months)
 - d. High response rate (>70%) with durable responses (median DoR ~29 months)
4. Which of the following drug types best describes the mechanism of action of linvoseltamab?
 - a. BCMA-targeted antibody-drug conjugate
 - b. CD3 x BCMA bispecific antibody
 - c. BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
 - d. GPRC5D-targeted antibody-drug conjugate
 - e. CD3 x GPRC5D bispecific antibody
 - f. GPRC5D-targeted CAR T-cell therapy
 - g. Cereblon E3 ligase modulatory drug
5. In the Phase III CARTITUDE-4 trial, ciltacabtagene autoleucel yielded which of the following overall survival outcomes in comparison to physician's choice of pomalidomide/bortezomib/dexamethasone or daratumumab/pomalidomide/dexamethasone for patients with R/R MM who had received at least 1 prior line of therapy and whose disease was refractory to lenalidomide?
 - a. No difference
 - b. A numerical but nonsignificant trend in improvement
 - c. A statistically significant improvement